About
Retension Pharmaceuticals is a Phase II clinical stage biopharmaceutical company developing orally administered selective phosphodiesterase type 5 inhibitors to treat vascular disorders by improving vascular function.
Explore Retension Pharmaceuticals's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.